THThomas H. Hostetter

Thomas H. Hostetter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas H. Hostetter has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Michal L. Melamed

    Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA

    2 shared publications
  • A. Raff

    Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, Room 615, Ullmann Building, 1300 Morris Park Ave, Bronx, NY 10461, USA

    1 shared publication
  • Andrew S. Levey

    Tufts University School of Medicine, Tufts New England Medical Center, Boston, MA

    1 shared publication
  • Carolyn Bauer

    1 shared publication
  • Katalin Susztak

    Department of Medicine, Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania

    1 shared publication
  • Ladan Golestaneh

    Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA

    1 shared publication

Latest Publications

  • Open Access

    Clinical Impact of Reporting Estimated Glomerular Filtration Rates

    by Thomas H. Hostetter, Andrew S. Levey, Lesley A Stevens


  • Methylamine clearance by haemodialysis is low

    by M. P. Ponda, Z. Quan, M. L. Melamed, A. Raff, T. W. Meyer, T. H. Hostetter

    Dialysis adequacy is currently judged by measures of urea clearance. However, urea is relatively non-toxic and has properties distinct from large classes of other retained solutes. In particular, intracellularly sequestered solutes are likely to behave differently than urea. We studied an example of this class, the aliphatic amine monomethylamine (MMA), in stable haemodialysis outpatients (n = 10) using an HPLC-based assay. Mean MMA levels pre-dialysis in end-stage renal disease subjects were 76 +/- 15 microg/L compared to 32 +/- 4 microg/L in normal subjects (n = 10) (P < 0.001). Mean urea reduction was 62% while the reduction ratio for MMA was 43% (P < 0.01). MMA levels rebounded in the 1 hour post-dialytic period to 85% of baseline, whereas urea levels rebounded only to 47% of baseline. MMA had a much larger calculated volume of distribution compared to urea, consistent with intracellular sequestration. Measures of intra-red blood cell (RBC) MMA concentrations confirmed greater levels in RBCs than in plasma with a ratio of 4.9:1. Because of the intracellular sequestration of MMA, we calculated its clearance using that amount removed from whole blood. Clearances for urea averaged 222 +/- 41 ml/min and for MMA 121 +/- 14 ml/min, while plasma clearance for creatinine was 162 +/- 20 ml/min (P < 0.01, for all differences). Using in vitro dialysis, in the absence of RBCs, solute clearance rates were similar: 333 +/- 6, 313 +/- 8 and 326 +/- 4 ml/min for urea, creatinine and MMA, respectively. These findings suggest that the lower MMA clearance relative to creatinine in vivo is a result of MMA movement into RBCs within the dialyser blood path diminishing its removal by dialysis. In conclusion, we find that, in conventional haemodialysis, MMA is not cleared as efficiently as urea or creatinine and raise the possibility that RBCs may limit its dialysis not merely by failing to discharge it, but by further sequestering it as blood passes through the dialyser.


  • Uremic memory: the role of acute kidney injury in long-term outcomes

    by Ladan Golestaneh, Michal L. Melamed, Thomas H. Hostetter


  • Open Access

    eGFR

    by Michal L. Melamed, Carolyn Bauer, Thomas H. Hostetter

    Reporting estimated glomerular filtration rate (eGFR) with serum creatinine simply provides the information for which the serum creatinine was ordered in the first place. Mass or universal screening is not the purpose of eGFR reporting. Furthermore, such mass screening does not seem justified. Rather, testing of high-risk groups with eGFR and urinary albumin is useful. Population estimates of the prevalence of chronic kidney disease in the United States that use the Kidney Disease Outcomes Quality Initiative staging system lead to disturbingly high estimates. Many of these people are elderly with marginally depressed GFRs and for whom there are no known therapeutic implications. However, an even more disturbing fraction of people with serious and progressive renal disease are not diagnosed, counseled, or treated. Reporting of eGFR is only one tool in attempting to rectify this latter problem. Nephrologists need to educate patients and their primary care colleagues in the use of this tool.


  • Animal models of renal disease

    by K. Susztak, M. Bitzer, T.W. Meyer, T.H. Hostetter